New Data Gives Hope to Small Cell Lung Cancer Patients

About 13% of lung cancer patients have Small Cell Lung Cancer (SCLC). The prognosis of this disease is very poor with 5-year survival rates of 31% for limited-stage SCLC (LS-SCLC) and 2% for extensive-stage SCLC (ES-SCLC). However, recent studies have shown that anti PD-L1 antibodies can extend overall survival of ES-SCLC patients when combined with platinum-etoposide treatment.

Professor Benjamin Besse, Head of the Cancer Medicine Department at Gustave Roussy Cancer Campus and Professor of Medical Oncology at Paris-Saclay University, Orsay, presented the late breaking data from EORTC-1417-LCG REACTION study: a phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer at the ESMO Virtual congress today.

All 125 patients (61 in experimental vs 64 in control arm) recruited previously responded to 2 cycles of platinum-etoposide. They were randomized into the control arm of 4 additional cycles of platinum-etoposide treatment or the experimental arm with 4 additional cycles of platinum-etoposide treatment combined with pembrolizumab and then up to 35 cycles of pembrolizumab. 119 (58 vs 61) patients were eligible and started at least one dose of the treatment. 19 patients had crossed over to the experimental arm at the time of progression. In the experimental arm, 43 % exhibited grade 3 to 5 adverse events vs 36% in the standard arm, median progression free survival was 4.7 vs. 5.4 months   and overall survival was 12.3 vs 10.4 months respectively. Besse concluded that even though the combination of etoposide and platinum with pembrolizumab was well tolerated, it did not improve progression free survival compared to standard treatment. However, the data did elude to the potential increase in overall survival, it should be noted that pembrolizumab needs to be introduced as first line treatment in order to benefit from this improvement.

“In REACTION, immunotherapy was added from the third cycle of chemotherapy,” said Besse. “Our results confirm the benefit of adding immunotherapy to first line chemotherapy in patients with extended SCLC. Our strategy is interesting for patient with PS2 at cycle 1 (thus unfit for immunotherapy) that will improve to PS 1 or 0 at cycle 3”.



Mini Oral Session – Non-metastatic NSCLC and other thoracic malignancies

LATE BREAKING ABSTRACT: REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

  • Presentation Number: LBA85
  • Date: 18 September 2020
  • Speaker: Benjamin Besse (Villejuif, CEDEX, France)


Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)